Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models
Topic overview
This preclinical study demonstrates that DPP4 inhibitors significantly reduce liver fibrosis and fat accumulation in a rat model of intestinal failure-associated liver disease (IFALD). The treatment improved survival rates and decreased fibrosis markers by suppressing TGF-β signaling, offering potential therapeutic insights for managing IFALD in patients dependent on parenteral nutrition.
Key takeaways
- DPP4 inhibitors reduced hepatic fibrosis and lipid accumulation in rat models of intestinal failure-associated liver disease (IFALD).
- DPP4-I treatment decreased α-SMA-positive cells and TGF-β levels, suggesting reduced hepatic stellate cell activation and fibrogenesis.
- Survival rate improved with DPP4-I therapy (87.5% vs 70% in controls) in the SBS + TPN model over 21 days.
- DPP4-I may protect against IFALD by inhibiting adipogenesis and suppressing pro-fibrotic TGF-β signaling pathways.
- This preclinical evidence supports investigating DPP4 inhibitors as a potential therapeutic strategy for IFALD in clinical settings.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models. GlobalCastMD Medical Library. 2024-10-29. https://dev.library.globalcastmd.com/article/9353?via_space=staycurrentmd
Comments